Attendee search 

Biovotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive physiological monitoring. The Biovotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable monitor of vital sign parameters, supported by integrated cloud services for data exchange and analysis. It is directed towards patients with chronic conditions featuring Biovotion’s patient-friendly, wearable monitoring concept.

The company holds internationally recognised know how, paired with an extensive IP portfolio in a number of fields, relevant to provide sensor technology and device development for continuous and non-invasive physiological monitoring, embedded into mHealth environments.

Abbott Biotech Ventures, Inc. (ABVI) is a subsidiary of Abbott dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, ABVI characterizes an investment’s success by its potential to significantly increase Abbott’s strategic growth, and not solely by its financial return. ABVI Investment Focus ABVI’s area of focus is on emerging biotech and pharmaceutical companies that have the potential to provide long-term strategic growth options for Abbott. Companies with programs ranging from pre-clinical (18 months prior to first-in-human) to early proof-of-concept are of highest interest for potential investment by ABVI. Given the early stage nature of these investments, ABVI will often syndicate with other venture capital investors or participate as a follow-on investor in a syndicated venture. ABVI Investment Criteria ABVI is interested in promising opportunities with large markets, differentiated competitive advantages, strong intellectual property protection, and viable clinical and reimbursement pathways. ABVI invests in areas that are strategic to Abbott such as neuroscience, immunology, cardiology, virology, and oncology, as well as emerging or more opportunistic areas of innovation that have the potential to complement Abbott’s existing portfolio or to expand Abbott’s future business reach. ABVI uses a rigorous, systematic process to identify, screen, and select opportunities. The team uses both internal and external experts to help assess technical and commercial opportunities for potential investments. In addition, ABVI looks for companies with a managerial team that has a strong track record in identifying and developing successful commercial opportunities.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.